Metastases

NICE Pathways

Interactive topic-based flowcharts that allow you to navigate our recommendations on any subject. Find out more about NICE Pathways.

• Metastatic malignant disease of unknown primary origin

• Metastatic spinal cord compression

NICE guidelines

Evidence-based recommendations on a range of health and care topics. Find out more about NICE guidelines

• Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)

  Id:

  CG104

  Published date:

  July 2010

• Metastatic spinal cord compression in adults: risk assessment, diagnosis and management (CG75)

  Id:

  CG75

  Published date:

  November 2008

Quality standards

Statements covering priority areas for quality improvement (including ways to measure quality). Find out more about Quality standards.

• Metastatic spinal cord compression in adults (QS56)

  Id:

  QS56

  Published date:

  February 2014

• Suspected cancer (QS124)

  Updated

  Yes

  Id:

  QS124

  Published date:

  June 2016

  Last updated:

  December 2017

Technology appraisal guidance

Assessments of the clinical and cost effectiveness of health technologies (most commonly medicines, but also medical devices, procedures and diagnostic techniques). Find out more about Technology appraisals guidance.

• Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

  Id:

  TA259

  Published date:

  June 2012

• Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

  Id:

  TA387

  Published date:

  April 2016

• Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)

  Id:

  TA310

  Published date:

  April 2014

• Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

  Id:

  TA307

  Published date:

  March 2014

• Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

  New

  Yes

  Id:

  TA520

  Published date:

  May 2018

• Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

  New

  Yes

  Id:

  TA492

  Published date:

  December 2017

• Avelumab for treating metastatic Merkel cell carcinoma (TA517)

  New

  Yes

  Id:

  TA517

  Published date:

  April 2018

• Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

  Id:

  TA178

  Published date:

  August 2009

• Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

  Id:

  TA118

  Published date:

  January 2007

• Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

  Id:

  TA214

  Published date:

  February 2011

• Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

  Id:

  TA263

  Published date:

  August 2012

• Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

  Id:

  TA212

  Published date:

  December 2010

• Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)

  Id:

  TA391

  Published date:

  May 2016

• Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)

  Id:

  TA439

  Published date:

  March 2017

• Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

  Id:

  TA473

  Published date:

  August 2017

• Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

  Id:

  TA242

  Published date:

  January 2012

• Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)

  Id:

  TA414

  Published date:

  October 2016

• Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)

  Id:

  TA321

  Published date:

  October 2014

• Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

  Id:

  TA265

  Published date:

  October 2012

• Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

  Id:

  TA101

  Published date:

  June 2006

• Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

  Id:

  TA316

  Published date:

  July 2014

• Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

  Id:

  TA377

  Published date:

  January 2016

• Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

  New

  Yes

  Id:

  TA515

  Published date:

  March 2018

• Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

  Id:

  TA423

  Published date:

  December 2016

• Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)

  Id:

  TA258

  Published date:

  June 2012

• Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)

  Id:

  TA449

  Published date:

  June 2017

• Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

  Id:

  TA239

  Published date:

  December 2011

• Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

  New

  Yes

  Id:

  TA503

  Published date:

  January 2018

• Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)

  Id:

  TA192

  Published date:

  July 2010

• Gemcitabine for the treatment of metastatic breast cancer (TA116)

  Id:

  TA116

  Published date:

  January 2007

• Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

  Id:

  TA61

  Published date:

  May 2003

• Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)

  Id:

  TA209

  Published date:

  November 2010

• Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)

  Id:

  TA86

  Published date:

  October 2004

• Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

  Id:

  TA268

  Published date:

  December 2012

• Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

  Id:

  TA319

  Published date:

  July 2014

• Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)

  Id:

  TA257

  Published date:

  June 2012

• Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)

  Id:

  TA411

  Published date:

  September 2016

• Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

  Id:

  TA347

  Published date:

  July 2015

• Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

  Id:

  TA484

  Published date:

  November 2017

• Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

  Id:

  TA483

  Published date:

  November 2017

• Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

  Id:

  TA384

  Published date:

  February 2016

• Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

  New

  Yes

  Id:

  TA490

  Published date:

  November 2017

• Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

  Id:

  TA400

  Published date:

  July 2016

• Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

  Id:

  TA416

  Published date:

  October 2016

• Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

  Id:

  TA476

  Published date:

  September 2017

• Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

  New

  Yes

  Id:

  TA495

  Published date:

  December 2017

• Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)

  Id:

  TA240

  Published date:

  December 2011

• Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)

  Id:

  TA440

  Published date:

  April 2017

• Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

  Id:

  TA366

  Published date:

  November 2015

• Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

  New

  Yes

  Id:

  TA519

  Published date:

  April 2018

• Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA447)

  Id:

  TA447

  Published date:

  June 2017

• Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

  New

  Yes

  Id:

  TA509

  Published date:

  March 2018

• Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

  Id:

  TA412

  Published date:

  September 2016

• Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

  Id:

  TA403

  Published date:

  August 2016

• Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)

  Id:

  TA334

  Published date:

  February 2015

• Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

  Id:

  TA488

  Published date:

  November 2017

• Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

  New

  Yes

  Id:

  TA496

  Published date:

  December 2017

• Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

  Id:

  TA169

  Published date:

  March 2009

• Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

  Id:

  TA410

  Published date:

  September 2016

• Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

  Id:

  TA396

  Published date:

  June 2016

• Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

  Id:

  TA208

  Published date:

  November 2010

• Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

  Id:

  TA405

  Published date:

  August 2016

• Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

  Id:

  TA269

  Published date:

  December 2012

• Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

  Id:

  TA272

  Published date:

  January 2013

Diagnostics guidance

Evaluation of innovative medical diagnostic technologies, allowing the NHS to adopt clinically and cost-effective technologies rapidly and consistently. Find out more about Diagnostics guidance.

• EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

  Id:

  DG9

  Published date:

  August 2013

• Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

  Id:

  DG8

  Published date:

  August 2013

Interventional procedures guidance

Assessments of whether procedures are safe enough and work well enough for wider use in the NHS. Find out more about Interventional procedures guidance.

• Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver cancer (IPG488)

  Id:

  IPG488

  Published date:

  May 2014

• Cryotherapy for the treatment of liver metastases (IPG369)

  Id:

  IPG369

  Published date:

  December 2010

• Cytoreduction surgery followed by hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (IPG331)

  Id:

  IPG331

  Published date:

  February 2010

• Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)

  Id:

  IPG446

  Published date:

  March 2013

• Irreversible electroporation for treating liver metastases (IPG445)

  Id:

  IPG445

  Published date:

  February 2013

• Microwave ablation for treating liver metastases (IPG553)

  Id:

  IPG553

  Published date:

  April 2016

• Percutaneous cementoplasty for palliative treatment of bony malignancies (IPG179)

  Id:

  IPG179

  Published date:

  June 2006

Evidence summaries

Summaries of the best available evidence for selected new medicines, off-label use of licensed medicines and unlicensed medicines. Find out more about Evidence summaries.

• Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

  Id:

  ESNM13

  Published date:

  March 2013

• Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)

  Id:

  ESUOM50

  Published date:

  January 2016

Medtech innovation briefings

Information on device and diagnostic technologies to help local decision-making. Find out more about Medtech innovation briefings (MIBs).

• Caris Molecular Intelligence for guiding cancer treatment (MIB120)

  Id:

  MIB120

  Published date:

  September 2017

• OSNA for colon cancer staging (MIB77)

  Id:

  MIB77

  Published date:

  August 2016

• Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)

  New

  Yes

  Id:

  MIB137

  Published date:

  January 2018

In development

• Abiraterone for the treatment of metastatic, castrate-resistant prostate cancer following previous cytotoxic chemotherapy TA259

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  October 2018

• Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy [ID1327]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  June 2018

• Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Atezolizumab with gemcitabine and carboplatin for treating metastatic urothelial bladder cancer [ID1206]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Brain tumours (primary) and brain metastases in adults

  New

  Yes

  Programme:

  NICE guideline

  Expected publication date:

  July 2018

• Breast cancer (brain metastases) - etirinotecan pegol [ID881]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID923]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  April 2019

• Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Lung cancer (non-small-cell, EGFR T790M-positive, metastatic, treated) - rociletinib [ID883]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Neuroendocrine tumours (metastatic, unresectable, progressive) - 177 Lu-dotatate [ID1224]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  July 2018

• Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Nivolumab for treating metastatic or unresectable urothelial cancer after platinum-based chemotherapy [ID995]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  July 2018

• Nivolumab with ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  October 2018

• Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable [ID1209]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  June 2018

• Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

• Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (CDF Review of TA447) [ID1349]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  July 2018

• Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (ID1140)

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  December 2018

• Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

Proposed

• Pembrolizumab with axitinib for untreated metastatic renal cell carcinoma ID1426

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

New guidance and advice

Guidance and advice added since November 2017

• Abiraterone for the treatment of metastatic, castrate-resistant prostate cancer following previous cytotoxic chemotherapy TA259

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  October 2018

  Status:

  In development

• Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

  New

  Yes

  Id:

  TA520

  Programme:

  Technology appraisal guidance

  Published date:

  May 2018

• Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Atezolizumab for treating metastatic urothelial cancer after platinum-based chemotherapy [ID1327]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  June 2018

  Status:

  In development

• Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

  New

  Yes

  Id:

  TA492

  Programme:

  Technology appraisal guidance

  Published date:

  December 2017

• Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Atezolizumab with gemcitabine and carboplatin for treating metastatic urothelial bladder cancer [ID1206]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Avelumab for treating metastatic Merkel cell carcinoma (TA517)

  New

  Yes

  Id:

  TA517

  Programme:

  Technology appraisal guidance

  Published date:

  April 2018

• Brain tumours (primary) and brain metastases in adults

  New

  Yes

  Programme:

  NICE guideline

  Expected publication date:

  July 2018

  Status:

  In development

• Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID923]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  April 2019

  Status:

  In development

• Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

  New

  Yes

  Id:

  TA515

  Programme:

  Technology appraisal guidance

  Published date:

  March 2018

• Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

  New

  Yes

  Id:

  TA503

  Programme:

  Technology appraisal guidance

  Published date:

  January 2018

• Neuroendocrine tumours (metastatic, unresectable, progressive) - 177 Lu-dotatate [ID1224]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  July 2018

  Status:

  In development

• Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Nivolumab for treating metastatic or unresectable urothelial cancer after platinum-based chemotherapy [ID995]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  July 2018

  Status:

  In development

• Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

  New

  Yes

  Id:

  TA490

  Programme:

  Technology appraisal guidance

  Published date:

  November 2017

• Nivolumab with ipilimumab for treating metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  October 2018

  Status:

  In development

• Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

  New

  Yes

  Id:

  TA495

  Programme:

  Technology appraisal guidance

  Published date:

  December 2017

• Pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable [ID1209]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  June 2018

  Status:

  In development

• Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  TBC

  Status:

  In development

• Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)

  New

  Yes

  Id:

  TA519

  Programme:

  Technology appraisal guidance

  Published date:

  April 2018

• Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer (CDF Review of TA447) [ID1349]

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  July 2018

  Status:

  In development

• Pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck (ID1140)

  New

  Yes

  Programme:

  Technology appraisal guidance

  Expected publication date:

  December 2018

  Status:

  In development

• Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

  New

  Yes

  Id:

  TA509

  Programme:

  Technology appraisal guidance

  Published date:

  March 2018

• Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)

  New

  Yes

  Id:

  MIB137

  Programme:

  Medtech innovation briefing

  Published date:

  January 2018

• Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

  New

  Yes

  Id:

  TA496

  Programme:

  Technology appraisal guidance

  Published date:

  December 2017

Updated guidance and advice

Guidance and advice updated since November 2017

• Suspected cancer (QS124)

  Updated

  Yes

  Id:

  QS124

  Programme:

  Quality standard

  Published date:

  June 2016

  Last updated:

  December 2017

Register as a stakeholder

Stakeholders can comment on draft guidance and participate in workshops and events.

Register now